Mergers & Acquisitions ·
Drugs Made In America Acquisition Corp. amends merger with Power Analytics Global to $1.71B standalone valuation
DMAADrugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. and Power Analytics Global Corp entered into Amendment No. 1 to their Merger Agreement, establishing a Standalone Closing Valuation of US$1.71 billion if the proposed acquisition of APQC Inc is not completed by November 1, 2026. The amendment removes the APQC completion condition upon such a Reversion Event and appoints Joel A. Gallo as independent evaluator to provide a fairness opinion for the standalone valuation. The prior engagement was terminated because the required intellectual property valuation necessitated a dual opinion structure. This transaction involves a blank check company seeking to merge with an analytics firm.